(Q50660059)

17 March 2018

title

Analysis of varicella vaccine breakthrough rates: implications for the effectiveness of immunisation programmes. (English)

1 reference

17 March 2018

author name string

Brisson M

1

1 reference

17 March 2018

Edmunds WJ

2

1 reference

17 March 2018

Gay NJ

3

1 reference

17 March 2018

Law B

4

1 reference

17 March 2018

De Serres G

5

1 reference

17 March 2018

language of work or name

English

0 references

publication date

1 June 2000

1 reference

17 March 2018

published in

Vaccine

1 reference

17 March 2018

volume

18

1 reference

17 March 2018

issue

25

1 reference

17 March 2018

page(s)

2775-2778

1 reference

17 March 2018

Study designs for evaluating different efficacy and effectiveness aspects of vaccines

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900100-6

7 January 2021

Imperfect vaccines and herd immunity to HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900100-6

7 January 2021

Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900100-6

7 January 2021

The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900100-6

7 January 2021

Live attenuated varicella vaccine: Immunization of healthy children with the OKA strain

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900100-6

7 January 2021

Varicella vaccine trials in healthy children. A summary of comparative and follow-up studies

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900100-6

7 January 2021

Live attenuated varicella virus vaccine. Efficacy trial in healthy children

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900100-6

7 January 2021

Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900100-6

7 January 2021

Over five-year follow-up of Oka/Merck varicella vaccine recipients in 465 infants and adolescents.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900100-6

7 January 2021

A long-term prospective study of varicella vaccine in healthy children

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900100-6

7 January 2021

Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900100-6

7 January 2021

10.1016/S0264-410X(00)00100-6

Identifiers

DOI

1 reference

17 March 2018

PubMed ID

10812218

1 reference

17 March 2018